Finding new small molecules to help degrade specific proteins in the body
Chemical Proteomics Approach to Discover Novel Small Molecule E3 Ligase recruiters for Targeted Protein degradation (TPD)
This study is looking into a new way to help treat diseases by finding small molecules that can help your body get rid of harmful proteins, which could lead to better treatments for conditions that don’t have good options right now.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10911246 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapeutic approach called targeted protein degradation (TPD), which aims to improve how we treat diseases by using small molecules to direct the body's cellular machinery to eliminate harmful proteins. The project seeks to discover novel E3 ligase recruiters that can bind to these proteins, making them targets for degradation. By exploring various chemical interactions, including those with cysteine and other amino acids, the research aims to expand the range of proteins that can be effectively targeted. This could lead to innovative treatments for conditions that currently lack effective therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with diseases caused by proteins that are currently difficult to target with existing therapies.
Not a fit: Patients with conditions that do not involve the proteins targeted by this research may not benefit from the findings.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for diseases caused by undruggable proteins, potentially improving patient outcomes.
How similar studies have performed: Other research has shown promise in using similar chemical proteomic approaches to target E3 ligases, indicating potential for success in this area.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Chang, Jaewon — Emory University
- Study coordinator: Chang, Jaewon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.